The Cooper Companies, Inc. (NASDAQ:COO) Receives Average Rating of “Hold” from Brokerages

The Cooper Companies, Inc. (NASDAQ:COO) has received an average rating of “Hold” from the sixteen ratings firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $81.3077.

COO has been the topic of a number of research analyst reports. Needham & Company LLC decreased their target price on Cooper Companies from $101.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday, June 5th. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research report on Friday, June 5th. Wells Fargo & Company reiterated a “sell” rating and set a $66.00 target price (down from $82.00) on shares of Cooper Companies in a research report on Friday, June 5th. The Goldman Sachs Group set a $61.00 target price on Cooper Companies in a research report on Wednesday, May 27th. Finally, Citigroup reissued a “neutral” rating and set a $69.00 price objective (down from $80.00) on shares of Cooper Companies in a research note on Thursday, May 28th.

Cooper Companies Price Performance

Shares of COO opened at $65.05 on Thursday. Cooper Companies has a twelve month low of $58.89 and a twelve month high of $89.83. The stock’s 50 day moving average is $64.58 and its two-hundred day moving average is $74.10. The firm has a market capitalization of $12.69 billion, a PE ratio of 55.13, a P/E/G ratio of 1.76 and a beta of 0.87. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.11. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The business’s revenue was up 7.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.96 EPS. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Research analysts anticipate that Cooper Companies will post 4.63 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COO. JANA Partners Management LP bought a new stake in Cooper Companies during the third quarter valued at $166,917,000. Alecta Tjanstepension Omsesidigt increased its stake in Cooper Companies by 15.8% during the third quarter. Alecta Tjanstepension Omsesidigt now owns 1,563,000 shares of the medical device company’s stock valued at $107,112,000 after purchasing an additional 213,500 shares during the last quarter. DAVENPORT & Co LLC increased its stake in Cooper Companies by 1,359.7% during the fourth quarter. DAVENPORT & Co LLC now owns 567,203 shares of the medical device company’s stock valued at $46,642,000 after purchasing an additional 528,346 shares during the last quarter. Swiss Life Asset Management Ltd increased its stake in Cooper Companies by 63.9% during the third quarter. Swiss Life Asset Management Ltd now owns 49,409 shares of the medical device company’s stock valued at $3,387,000 after purchasing an additional 19,264 shares during the last quarter. Finally, Fluent Financial LLC bought a new stake in Cooper Companies during the fourth quarter valued at $3,517,000. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.